Biotech’s groove is back for 2026 as XBI surges on M&A and lower rates
Biotech’s groove is back for 2026 as XBI surges on M&A and lower rates
Biotech’s groove is back for 2026 as XBI surges on M&A and lower rates
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page